Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd has informed shareholders about the distribution of its Integrated Annual Report for FY 2025-26 and the Notice for its 37th Annual General Meeting (AGM). This communication is directed to shareholders whose email addresses are not registered. The AGM is scheduled for July 31, 2026, via Video Conferencing. The company also highlighted SEBI regulations regarding KYC updates for physical shareholders, stating that dividends will be withheld if KYC is not updated post-April 1, 2024, and will only be paid electronically from November 19, 2025, onwards. Shareholders can access the report and notice via web-links and QR codes provided.

Advanced Enzyme Technologies Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-2026. The report, which is an integral part of the Integrated Annual Report, details the company's performance across various ESG parameters. Key disclosures include its corporate identification, business activities focused on enzymes and probiotics contributing 100% to turnover, and operational presence across 4 plants and 2 offices in India, with exports to 52 countries. The company reported a total of 400 employees and 362 workers as of March 31, 2026, with specific data on gender representation and inclusion of differently-abled individuals. The BRSR is available on the company's website.

Advanced Enzyme Technologies Ltd. has filed its Integrated Annual Report for the financial year 2025-2026. The report includes the Notice of the 37th Annual General Meeting (AGM) scheduled for July 31, 2026, to be held via Video Conference. The cut-off date for determining voting eligibility is July 24, 2026. The report details the company's performance, product portfolio, corporate framework, financial statements (standalone and consolidated), and management discussion and analysis. It highlights a focus on scaling innovation and sustainability, with market capitalization reported at ₹28,575 million as of March 31, 2026. The company also announced a proposed dividend of ₹4 per share and an interim dividend of ₹1.35 per share.

Advanced Enzyme Technologies Ltd has announced its 37th Annual General Meeting (AGM) will be held on Friday, July 31, 2026, at 10:00 a.m. IST. The meeting will be conducted through Video Conference or Other Audio Visual Means. Key agenda items include the adoption of the Audited Financial Statements for FY26 (Standalone and Consolidated), declaration of a final dividend of ₹1.35 per equity share, re-appointment of Ms. Rasika Rathi as Director, reappointment of M/s. MSKA & Associates LLP as Statutory Auditors for a second term of 5 years, and re-appointment of Mr. Mukund Madhusudan Kabra as Whole-time Director for 5 years from April 1, 2027. Additionally, the appointment of Mr. Pradip Bhailal Shah as an Independent Director will be considered.

Advanced Enzyme Technologies Ltd has announced the record date for its final dividend payment. The company has fixed Friday, July 24, 2026, as the record date to determine shareholders eligible for the final dividend of ₹1.35 per equity share for the financial year 2025-26. This dividend, if approved at the 37th Annual General Meeting (AGM) scheduled for July 31, 2026, will be paid on or after August 3, 2026. The AGM will be conducted via Video Conference or Other Audio Visual Means.

Advanced Enzyme Technologies Ltd. has announced that its 37th Annual General Meeting (AGM) will be held on Friday, July 31, 2026, via Video Conference/Other Audio Visual Means. The company also confirmed the Record Date for dividend entitlement as Friday, July 24, 2026. If approved at the AGM, the recommended final dividend of ₹1.35 per equity share for FY26 will be paid on or after August 03, 2026. The ISIN for the security is INE837H01020.

Advanced Enzyme Technologies Ltd has announced the closure of its trading window effective July 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations 2015 and the company's internal code for preventing insider trading. The trading window will remain shut until 48 hours after the announcement of the company's financial results for the quarter ended June 30, 2026. This measure is standard practice to prevent potential insider trading during periods of sensitive financial information disclosure.

Advanced Enzyme Technologies Ltd has announced that Ms. Rajshree Patel will complete her second consecutive term as an Independent Director on June 11, 2026. Consequently, she will cease to be a Director of the Company on that date. This cessation is due to the completion of her tenure as per the company's governance policies and SEBI regulations.

Advanced Enzyme Technologies Ltd has completed an additional investment of ₹2.5 million in its wholly owned subsidiary, Advanced Nutrazyme Private Limited (ANPL). This investment was made through participating in ANPL's rights issue, acquiring 2,50,000 Equity Shares of ₹10 each. Following this transaction, Advanced Enzyme's total investment in ANPL has risen to ₹3 million, represented by 3,00,000 Equity Shares of ₹10 each. This move strengthens the subsidiary's capital base and Advanced Enzyme's overall stake.

Advanced Enzyme Technologies Ltd announced its audited financial results for Q4 and the year ended March 2026. Consolidated revenue for FY26 increased by 17% to ₹7,458 million. Q4 FY26 revenue stood at ₹2,034 million, a 22% increase YoY. EBITDA for Q4 FY26 was ₹632 million, up 39% YoY, with an EBITDA margin of 31%. PAT for Q4 FY26 grew by 69% to ₹453 million, with a PAT margin of 22%. EPS for Q4 FY26 was ₹3.84, compared to ₹2.37 in Q4 FY25.